NEW YORK (GenomeWeb News) – Vermillion said today that it has obtained permits and completed regulatory processes required for opening a clinical reference laboratory.

In a filing with the US Securities and Exchange Commission, the company said that the lab, Aspira Labs, "will offer tests related to gynecologic oncology and women’s health," including its OVA1 ovarian cancer test.

The lab will be led by Herbert Fritsche, formerly clinical chemistry section chief in the Department of Pathology and Laboratory Medicine at MD Anderson Cancer Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.